A phase 2 study of capecitabine and concomitant radiation in women with advanced breast cancer.

[1]  N. Dunlap,et al.  Efficacy of concurrent chemoradiotherapy for patients with locally recurrent or advanced inoperable breast cancer. , 2015, Clinical breast cancer.

[2]  F. Cardoso,et al.  Management of locally advanced breast cancer—perspectives and future directions , 2015, Nature Reviews Clinical Oncology.

[3]  E. Perez,et al.  Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  B. Yalcin.  Overview on locally advanced breast cancer: defining, epidemiology, and overview on neoadjuvant therapy. , 2013, Experimental oncology.

[5]  N. Mitsuhashi,et al.  The role of chemoradiotherapy in patients with unresectable T4 breast tumors , 2013, Breast Cancer.

[6]  C. Balleyguier,et al.  Effect of preoperative rescue concomitant FUN/XUN-based chemo-radiotherapy for neoadjuvant chemotherapy-refractory breast cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  E. Elkin,et al.  Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era. , 2010, International journal of radiation oncology, biology, physics.

[8]  W. Woodward,et al.  Overcoming radiation resistance in inflammatory breast cancer , 2010, Cancer.

[9]  W. Woodward,et al.  Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. , 2008, International journal of radiation oncology, biology, physics.

[10]  W. Woodward,et al.  The role of locoregional therapy in inflammatory breast cancer. , 2008, Seminars in oncology.

[11]  R. Arcuri,et al.  A Phase II Study of Second-Line Neoadjuvant Chemotherapy With Capecitabine and Radiation Therapy for Anthracycline-Resistant Locally Advanced Breast Cancer , 2007, American journal of clinical oncology.

[12]  Jeffrey S. Morris,et al.  Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. , 2006, International journal of radiation oncology, biology, physics.

[13]  S. Liauw,et al.  Inflammatory breast carcinoma: Outcomes with trimodality therapy for nonmetastatic disease , 2004, Cancer.

[14]  Henry M Kuerer,et al.  Locoregional treatment outcomes for inoperable anthracycline-resistant breast cancer. , 2002, International journal of radiation oncology, biology, physics.

[15]  H. Ishitsuka,et al.  X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  H. Ishitsuka,et al.  Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. , 1998, Biochemical pharmacology.